Differentiating the Sodium‐Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling

The aim of this research was to differentiate dapagliflozin, empagliflozin, and canagliflozin based on their capacity to inhibit sodium‐glucose cotransporter (SGLT) 1 and 2 in patients with type 2 diabetes using a previously developed quantitative systems pharmacology model of renal glucose filtrati...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:CPT Pharmacometrics Syst Pharmacol
Autores principales: Sokolov, Victor, Yakovleva, Tatiana, Chu, Lulu, Tang, Weifeng, Greasley, Peter J., Johansson, Susanne, Peskov, Kirill, Helmlinger, Gabriel, Boulton, David W., Penland, Robert C.
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7180004/
https://ncbi.nlm.nih.gov/pubmed/32064793
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/psp4.12498
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares